J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (4)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kostapanos, M. S.
Right arrow Articles by Elisaf, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kostapanos, M. S.
Right arrow Articles by Elisaf, M.

CLINICAL STUDIES

Rosuvastatin Increases {alpha}-1 Microglobulin Urinary Excretion in Patients With Primary Dyslipidemia

Michael S. Kostapanos, MD, Haralampos J. Milionis, MD, Irene Gazi, MD, Christine Kostara, PhD, Eleni T. Bairaktari, PhD and Moses Elisaf, MD, FRSH, FASA

From the Department of Internal Medicine (Dr Kostapanos, Dr Milionis, Dr Gazi, Prof Elisaf) and the Laboratory of Clinical Chemistry (Dr Kostara, Dr Bairaktari), School of Medicine, University of Ioannina, Ioannina, Greece.

The renoprotective effect of statins has been recently disputed because of observations of proteinuria associated with rosuvastatin treatment, the newest drug of the class. Statin-induced proteinuria findings were mainly based on crudely quantitative dipstick assays. The authors quantitatively evaluated the effect of rosuvastatin at the recommended starting dose of 10 mg/d, on urine protein excretion in patients with primary dyslipidemia. Serum lipid and nonlipid parameters as well as urinary electrolyte, creatinine, and protein (total, albumin, immunoglobulin G, and {alpha}-1 microglobulin) levels were measured in 40 patients treated with rosuvastatin and 30 controls at baseline and after 12 weeks. The protein-to-creatinine ratios were used to assess urinary protein excretion. Rosuvastatin improved the lipid profile, produced no deterioration of kidney function, but induced a small but significant increase in the excretion of {alpha}-1 microglobulin (by 16%, P < .05) indicating that statin-related proteinuria involves low-molecular-weight proteins and is of proximal tubular origin.

Key Words: Rosuvastatin • proteinuria • albumin • alpha-1 microglobulin

Address for reprints: Moses S. Elisaf, MD, FRSH, FASA, Department of Internal Medicine, School of Medicine, University of Ioannina, 451 10 Ioannina, Greece; e-mail: hmilioni{at}cc.uoi.gr.




This article has been cited by other articles:


Home page
 J CARDIOVASC PHARMACOL THERHome page
M. S. Kostapanos, H. J. Milionis, and M. S. Elisaf
An Overview of the Extra-Lipid Effects of Rosuvastatin
Journal of Cardiovascular Pharmacology and Therapeutics, September 1, 2008; 13(3): 157 - 174.
[Abstract] [PDF]

Home page
 J CARDIOVASC PHARMACOL THERHome page
M. S. Kostapanos, H. J. Milionis, V. G. Saougos, K. G. Lagos, C. Kostara, E. T. Bairaktari, and M. S. Elisaf
Dose-Dependent Effect of Rosuvastatin Treatment on Urinary Protein Excretion
Journal of Cardiovascular Pharmacology and Therapeutics, December 1, 2007; 12(4): 292 - 297.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by the American College of Clinical Pharmacology